124 related articles for article (PubMed ID: 30624297)
1. A Multiplex HIV Incidence Assay for Inferring Recent HIV-1 Transmission and Time of Infection.
Curtis KA; Campbell EM; Hanson DL; Rudolph DL; Duwve J; J Blosser S; Gentry J; Lovchik J; Peters PJ; Owen SM; Switzer WM
J Acquir Immune Defic Syndr; 2019 Apr; 80(4):454-460. PubMed ID: 30624297
[TBL] [Abstract][Full Text] [Related]
2. Development and characterization of a bead-based, multiplex assay for estimation of recent HIV type 1 infection.
Curtis KA; Kennedy MS; Charurat M; Nasidi A; Delaney K; Spira TJ; Owen SM
AIDS Res Hum Retroviruses; 2012 Feb; 28(2):188-97. PubMed ID: 21585287
[TBL] [Abstract][Full Text] [Related]
3. Anti-HIV-1 antibodies based confirmatory results in Wuhan, China, 2012-2018.
Liu P; Tang L; Kong WH; Zhu ZR; Xiao P; Wang X; Zhou W; Liu MQ
PLoS One; 2020; 15(9):e0238282. PubMed ID: 32915788
[TBL] [Abstract][Full Text] [Related]
4. Strongly enhanced sensitivity of a direct anti-HIV-1/-2 assay in seroconversion by incorporation of HIV p24 ag detection: a new generation vironostika HIV Uni-Form II.
van Binsbergen J; Keur W; Siebelink A; van de Graaf M; Jacobs A; de Rijk D; Nijholt L; Toonen J; Gürtler LG
J Virol Methods; 1998 Dec; 76(1-2):59-71. PubMed ID: 9923740
[TBL] [Abstract][Full Text] [Related]
5. Assessment of antibody assays for identifying and distinguishing recent from long-term HIV type 1 infection.
Parekh BS; Pau CP; Kennedy MS; Dobbs TL; McDougal JS
AIDS Res Hum Retroviruses; 2001 Jan; 17(2):137-46. PubMed ID: 11177393
[TBL] [Abstract][Full Text] [Related]
6. Reactivity of a new HIV-1 group O third generation A-HIV-1/-2 assay with an unusual HIV-1 seroconversion panel and HIV-1 group O/group M subtyped samples.
van Binsbergen J; Keur W; vd Graaf M; Siebelink A; Jacobs A; de Rijk D; Toonen J; Zekeng L; Afane Ze E; Gürtler LG
J Virol Methods; 1997 Dec; 69(1-2):29-37. PubMed ID: 9504748
[TBL] [Abstract][Full Text] [Related]
7. HIV. The modern era of HIV-1 vaccine development.
Mascola JR
Science; 2015 Jul; 349(6244):139-40. PubMed ID: 26160931
[No Abstract] [Full Text] [Related]
8. Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design.
Parren PW; Gauduin MC; Koup RA; Poignard P; Fisicaro P; Burton DR; Sattentau QJ
Immunol Lett; 1997 Jun; 57(1-3):105-12. PubMed ID: 9232434
[TBL] [Abstract][Full Text] [Related]
9. Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design".
Parren PW; Gauduin MC; Koup RA; Poignard P; Sattentau QJ; Fisicaro P; Burton DR
Immunol Lett; 1997 Jul; 58(2):125-32. PubMed ID: 9271324
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic value of antibodies against HIV-1 proteins in seropositive drug addicts tested by the western blotting method].
Swiderska H; Kalinowska B
Przegl Epidemiol; 1992; 46(1-2):19-25. PubMed ID: 1475386
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
[TBL] [Abstract][Full Text] [Related]
12. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
Richardson TM; Stryjewski BL; Broder CC; Hoxie JA; Mascola JR; Earl PL; Doms RW
J Virol; 1996 Feb; 70(2):753-62. PubMed ID: 8551612
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity and specificity of anti-HIV ELISA employing recombinant (p24, p66, gp120) and synthetic (gp41) viral antigenic peptides.
Filice G; Soldini L; Orsolini P; Razzini E; Gulminetti R; Campisi D; Chiapparoli L; Cattaneo E; Achilli G
Microbiologica; 1991 Jul; 14(3):185-94. PubMed ID: 1717811
[TBL] [Abstract][Full Text] [Related]
14. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression.
Zwart G; van der Hoek L; Valk M; Cornelissen MT; Baan E; Dekker J; Koot M; Kuiken CL; Goudsmit J
Virology; 1994 Jun; 201(2):285-93. PubMed ID: 7514319
[TBL] [Abstract][Full Text] [Related]
15. [An analysis of the blood sera of patients infected with HIV-1 for the presence of antibodies to the gp120 and gp41 sequences].
Sergeev OV; Garaev MM
Zh Mikrobiol Epidemiol Immunobiol; 1995; (4):47-51. PubMed ID: 9381871
[TBL] [Abstract][Full Text] [Related]
16. Compartmentalization of the IgG immune response to HIV-1 in breast milk.
Becquart P; Hocini H; Garin B; Sépou A; Kazatchkine MD; Bélec L
AIDS; 1999 Jul; 13(11):1323-31. PubMed ID: 10449284
[TBL] [Abstract][Full Text] [Related]
17. Changes in HIV-specific antibody responses and neutralization titers in patients under ART.
Falkensammer B; Freissmuth D; Hübner L; Speth C; Dierich MP; Stoiber H
Front Biosci; 2007 Jan; 12():2148-58. PubMed ID: 17127452
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of human immunodeficiency virus type 1 antibody reactivity by western immunoblots: evaluation of relative antibody levels in seropositive individuals and mothers.
Geffin RB; Lai SH; Hutto C; Scott GB; Scott WA; Master M; Parks WP
J Infect Dis; 1992 Jan; 165(1):111-8. PubMed ID: 1727880
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
Corey L; McElrath MJ; Weinhold K; Matthews T; Stablein D; Graham B; Keefer M; Schwartz D; Gorse G
J Infect Dis; 1998 Feb; 177(2):301-9. PubMed ID: 9466515
[TBL] [Abstract][Full Text] [Related]
20. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.
Moore PL; Crooks ET; Porter L; Zhu P; Cayanan CS; Grise H; Corcoran P; Zwick MB; Franti M; Morris L; Roux KH; Burton DR; Binley JM
J Virol; 2006 Mar; 80(5):2515-28. PubMed ID: 16474158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
